title: Molecular markers for incidence, prognosis, and response to therapy.
abstract: Lung cancer is the most common malignancy in the United States and worldwide. In 2011, it is estimated that more than 221,000 people in the United States will be diagnosed with cancer of the lung and bronchus. For patients with early-stage disease, 5-year survival approaches only 50%. Recent advances using molecular, genetic, and proteomic profiling of lung tumors have enabled refining the prognosis for patients with non-small cell lung cancer. With targeted therapies, there is an opportunity to enhance long-term survival. This article discusses several key molecular markers used in the prognostication and treatment of non-small cell lung cancer.
authors.affiliation: Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Box 3043, Hock Plaza-2424 Erwin Road, Suite 403, Durham, NC 27710, USA.
authors.forename: Betty C
authors.initials: BC
authors.lastname: Tong
authors.forename: David H
authors.initials: DH
authors.lastname: Harpole
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000401:mortality / Q000628:therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D052138:Genes, Neoplasm / Q000235:genetics; D005819:Genetic Markers; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000401:mortality / Q000628:therapy*; D035683:MicroRNAs / Q000502:physiology; D046228:Microarray Analysis; D057285:Precision Medicine / Q000379:methods; D011379:Prognosis; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D040901:Proteomics; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D014408:Biomarkers, Tumor; D005819:Genetic Markers; D035683:MicroRNAs; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000077548:Anaplastic Lymphoma Kinase; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D020794:Receptor Protein-Tyrosine Kinases